



Deviation From SOP

Date: 8/10/21 **Affected SOPs:** ABID and RBC Antigen

Samples Involved: All samples requiring ABID and possible antigen typing.

Description: **Reason for Change:** The Molecular Lab evaluated their testing profiles. It was decided due to cost and low number of tests, to discontinue the use of the PreciseType/BioArray System. As of 8/10/21, they have worked through the all the reagents available. We cannot submit any samples for testing.

Immediate actions

A deviation has been documented and the team should be aware of these changes via MTS Training. The Blood Bank will deviate from practice in the following way:

- a) The Blood Bank will no longer sent samples to IUH Molecular Lab for "BioArray," but use Versiti Wisconsin for specific patient types. These types of samples would be patients with autoantibodies, sickle cell patients or complex serologic patients.
- b) The Blood Bank will continue with current practice per SOP to mark ABID testing as "send to BioArray" There is no change in our current practice to complete an ABID.
- c) At the time of supervisory review, then we will decide if the sample should be sent for RBC Molecular Testing or if the RBC phenotype testing should be tested by serologic methods.
- d) Serologic phenotype testing may be completed routinely or part of the investigation. Cell separations may be necessary for patient who have been transfused for patient phenotype testing.

Possible Effects: Impact to the Blood Bank:

- We will no longer be able to obtain a full RBC genotype on all antibody patients.
- We will have to submit particular patients for RBC Molecular testing with Versiti Wisconsin
- We will have to re-institute RBC phenotype testing on a routine basis or use the NEO for C, E, c, e and K testing.

Jayanna Slayten

Technologist/Supervisor Jay Slayten

Approved By _____